Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$1.75 -5.4%	$2.31	$0.98 ▼ $3.44	$70.58M	0.26	36,322 shs	51,279 shs
EXOZ eXoZymes	$9.78 +0.2%	$10.37	$8.50 ▼ $23.99	$82.03M	N/A	14,513 shs	465 shs
OTLC Oncotelic Therapeutics	$0.05 +3.0%	$0.05	$0.02 ▼ $0.07	$20.89M	-0.9	113,220 shs	60,478 shs
OTLK Oncobiologics	$2.63 -5.1%	$1.95	$0.87 ▼ $8.32	$88.29M	0.26	775,979 shs	2.35 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	-8.42%	-9.76%	-15.14%	+10.05%	-1.07%
EXOZ eXoZymes	+0.62%	-1.01%	+5.51%	-35.28%	+975,999,900.00%
OTLC Oncotelic Therapeutics	-2.56%	+11.74%	-2.37%	-17.50%	+115.22%
OTLK Oncobiologics	+18.38%	+41.33%	+27.06%	+62.94%	-64.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	0.3386 of 5 stars	0.0	3.0	0.0	0.0	1.1	1.7	0.0
OTLK Oncobiologics	1.8233 of 5 stars	3.4	2.0	0.0	0.0	2.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	0.00	N/A	N/A	N/A
EXOZ eXoZymes	0.00	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	0.00	N/A	N/A	N/A
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	264.33% Upside

Current Analyst Ratings Breakdown

Latest OTLC, OTLK, BYSI, and EXOZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	OTLK Oncobiologics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/20/2025	OTLK Oncobiologics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	N/A	N/A	N/A	N/A	($0.37) per share	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	$1.25 per share	N/A
OTLC Oncotelic Therapeutics	$70K	298.36	N/A	N/A	$0.02 per share	2.55
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	11/6/2025 (Estimated)
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	-134.50%	-81.63%	N/A
OTLC Oncotelic Therapeutics	-$4.52M	-$0.01	N/A	∞	N/A	N/A	-9.62%	-2.72%	N/A
OTLK Oncobiologics	-$75.37M	-$0.57	N/A	N/A	N/A	N/A	N/A	-335.21%	N/A

Latest OTLC, OTLK, BYSI, and EXOZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	OTLK Oncobiologics	-$0.42	-$0.44	-$0.02	-$0.55	$1.66 million	$1.51 million
8/13/2025	Q2 2025	BYSI BeyondSpring	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/12/2025	Q2 2025	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
OTLC Oncotelic Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	2.19	2.19
EXOZ eXoZymes	0.01	6.19	6.19
OTLC Oncotelic Therapeutics	N/A	0.01	0.01
OTLK Oncobiologics	N/A	0.72	0.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
EXOZ eXoZymes	N/A
OTLC Oncotelic Therapeutics	N/A
OTLK Oncobiologics	11.20%

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
EXOZ eXoZymes	72.41%
OTLC Oncotelic Therapeutics	39.22%
OTLK Oncobiologics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	80	40.33 million	28.51 million	Optionable
EXOZ eXoZymes	29	8.39 million	2.31 million	N/A
OTLC Oncotelic Therapeutics	20	409.52 million	248.91 million	Not Optionable
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable

OTLC, OTLK, BYSI, and EXOZ Headlines

Recent News About These Companies

Oncobiologics (NASDAQ:OTLK) Releases Earnings Results, Misses Estimates By $0.02 EPS

August 18 at 3:52 PM | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Earns Neutral Rating from Chardan Capital

August 17 at 8:29 AM | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Given "Neutral" Rating at Chardan Capital

August 17 at 3:31 AM | americanbankingnews.com

Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

August 14, 2025 | zacks.com

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

August 14, 2025 | globenewswire.com

Oncobiologics (OTLK) to Release Quarterly Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Oncobiologics, Inc. (NASDAQ:OTLK) Receives $9.60 Consensus Target Price from Analysts

August 8, 2025 | americanbankingnews.com

Oncobiologics (OTLK) Projected to Post Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Oncobiologics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Brokerages

August 5, 2025 | marketbeat.com

Oncobiologics (NASDAQ:OTLK) Trading Down 1.5% - Should You Sell?

August 3, 2025 | marketbeat.com

New Strong Buy Stocks for July 30th

July 30, 2025 | zacks.com

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

July 24, 2025 | globenewswire.com

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

July 22, 2025 | globenewswire.com

OTLK Outlook Therapeutics, Inc. - Seeking Alpha

July 2, 2025 | seekingalpha.com

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

July 1, 2025 | globenewswire.com

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

June 18, 2025 | globenewswire.com

Microsoft shares temp fix for Outlook crashes when opening emails

June 17, 2025 | bleepingcomputer.comB

CFA Institute 2025 Graduate Outlook Survey: Finance Top Career Choice

June 12, 2025 | tmcnet.com

Steve Wilks Pleased With Jets Defensive Outlook

June 12, 2025 | msn.com

Microsoft Outlook to block more risky attachments used in attacks

June 12, 2025 | bleepingcomputer.comB

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

June 11, 2025 | pharmaceutical-technology.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLC, OTLK, BYSI, and EXOZ Company Descriptions

BeyondSpring NASDAQ:BYSI

$1.75 -0.10 (-5.41%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 +0.01 (+0.57%)

As of 04:10 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

eXoZymes NASDAQ:EXOZ

$9.78 +0.02 (+0.20%)

As of 04:00 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Oncotelic Therapeutics OTCMKTS:OTLC

$0.05 +0.00 (+3.03%)

As of 12:11 PM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Oncobiologics NASDAQ:OTLK

$2.63 -0.14 (-5.05%)

Closing price 04:00 PM Eastern

Extended Trading

$2.64 +0.02 (+0.57%)

As of 07:02 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time